Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,290.00
Bid: 1,290.00
Ask: 1,296.00
Change: -8.00 (-0.62%)
Spread: 6.00 (0.465%)
Open: 1,272.00
High: 1,300.00
Low: 1,272.00
Prev. Close: 1,298.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Victrex plc - Q3 Interim Management Statement

6 Jul 2023 07:00

RNS Number : 1185F
Victrex PLC
06 July 2023
 
 

 

6 July 2023

Victrex plc - Q3 Interim Management Statement

Volumes lower on macro-economic weakness; further price improvement

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's Interim Management Statement for Q3 covers the period 1 April 2023 to 30 June 2023.

Performance summary - Q3 in line with guidance

As previously communicated in our trading update of 14 June 2023 and at our interim results, compared to a record prior year period, the Group is seeing ongoing macro-economic weakness and destocking across several end markets.

The Group continues to be well positioned for a macro-economic recovery.

Q3 saw further improvement in average selling prices (ASP), taking year-to-date ASP to £85/kg, supported by price increases, sales mix and currency. We now anticipate that full year ASP will be above £84/kg. This in turn, together with easing energy costs, means we are seeing gross margin improvement during the second half, compared to the prior year, but it will be slightly held back by lower asset utilisation.

Further progress in mega-programmes; E-mobility exceeding expectations

Further progress was seen in commercial milestones within our 'mega-programme' growth pipeline, particularly in E-mobility and Trauma. We now anticipate annual revenues in our E-mobility mega-programme will exceed our original expectations, reaching £5m in FY 2023. In Trauma, we are making good progress with our PEEK composite Trauma plates, serving growing demand in the US and Asia. Run-rates are building towards £1m revenue and further growth in both E-mobility and Trauma is expected in FY 2024.

Q3 performance:

· Q3 Group revenue down 23% to £72.2m (Q3 2022: £93.4m)

· Q3 Group volume down 38% to 818 tonnes (Q3 2022: 1,323 tonnes)

· Year to date Group revenue of £234.4m is 8% down on the prior year (2022 YTD: £253.5m), with YTD Group volume of 2,759 tonnes being 23% down on the prior year (2022 YTD: 3,586 tonnes)

· Q3 weakness driven by Electronics, Energy & Industrial and Value Added Resellers

· Aerospace seeing good growth; Automotive stable YTD

· Medical performing strongly; YTD revenue continues to track up double-digit

 

 

 

Financial position

Victrex retains a highly cash generative business model, which supports growth investment and shareholder returns. Capital expenditure this year is focused on our China manufacturing investments, with our new PEEK polymer facility having delivered first polymer ahead of commercial start up by the end of 2023. Total cash on 30 June 2023 was £27m, which includes £3.5m cash ringfenced in China investments. Capital expenditure will start to step down from FY 2024, supporting improving cashflows.

 

Outlook unchanged

Jakob Sigurdsson, Chief Executive of Victrex, said: "In line with our recent trading update, we continue to be impacted by ongoing macro-economic weakness and destocking in several end markets. Compared to a record prior year period, lower Q3 volumes were driven by Electronics, Energy & Industrial and Value Added Resellers. Aerospace and Medical continue to perform strongly, whilst Automotive is stable year-to-date.

 

"Overall, our Outlook is unchanged from what we recently communicated, with full-year adjusted (pre-exceptional) PBT expected to be in the range of £80m-£85m. As we move into the final quarter, strong average selling prices, mix, energy costs and cost discipline remain supportive, and we continue to be well-placed for when the macro-economic environment improves.

 

"On a medium to long term basis, we have a strong and diverse core business, growing commercialisation in our mega-programmes, capital investment which is set to reduce and support improving cash flows, and strong ESG credentials."

 

Victrex will report its Preliminary Results for 2023 on Tuesday 4 December 2023.

 

Analyst & investor call:

A call for analysts & investors will be held today, Thursday 6 July, at 08.30am UK time. To register for the call please follow this link:

https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=3197336&linkSecurityString=82f3181b0

 

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG

+44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

Ian Melling, Chief Financial Officer 

+44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTBCGDRISGDGXU
Date   Source Headline
28th Feb 202210:46 amRNSTotal Voting Rights
22nd Feb 20221:14 pmRNSDirector/PDMR Shareholding
17th Feb 202212:30 pmRNSDirector/PDMR Shareholding
15th Feb 202212:12 pmRNSHolding(s) in Company
11th Feb 202212:21 pmRNSResult of AGM
11th Feb 20227:00 amRNSAGM & Q1 Interim Management Statement
10th Feb 20222:06 pmRNSDirector/PDMR Shareholding
10th Feb 202210:15 amRNSHolding(s) in Company
31st Jan 202210:23 amRNSTotal Voting Rights
28th Jan 20223:23 pmRNSHolding(s) in Company
24th Jan 20223:54 pmRNSHolding(s) in Company
20th Jan 20229:21 amRNSAdditional Listing
18th Jan 20223:11 pmRNSDirector/PDMR Shareholding
6th Jan 20222:14 pmRNSAnnual Report and Accounts
6th Jan 20229:53 amRNSDirector/PDMR Shareholding
31st Dec 20219:00 amRNSTotal Voting Rights
17th Dec 20213:59 pmRNSHolding(s) in Company
17th Dec 202112:01 pmRNSDirector/PDMR Shareholding
16th Dec 20211:06 pmRNSDirector/PDMR Shareholding
13th Dec 202111:20 amRNSDirector/PDMR Shareholding
6th Dec 20217:00 amRNSVictrex plc – Preliminary Results 2021
1st Dec 20213:48 pmRNSBlock listing Interim Review
30th Nov 202111:39 amRNSTotal Voting Rights
18th Nov 20212:12 pmRNSDirector Declaration
17th Nov 202112:17 pmRNSDirector/PDMR Shareholding
9th Nov 20211:51 pmRNSDirector Declaration - Replacement
9th Nov 20219:00 amRNSDirector Declaration
29th Oct 20219:25 amRNSTotal Voting Rights
21st Oct 20217:00 amRNSVictrex signs up to SBTi
19th Oct 202111:13 amRNSDirector/PDMR Shareholding
15th Oct 20217:00 amRNSDirectorate Change
14th Oct 20217:00 amRNSTechnipFMC to acquire Victrex’s Magma equity
30th Sep 20212:22 pmRNSTotal Voting Rights
20th Sep 20217:00 amRNSChair-designate appointment
17th Sep 202110:51 amRNSDirector/PDMR Shareholding
31st Aug 202110:23 amRNSTotal Voting Rights
18th Aug 20214:11 pmRNSDirector/PDMR Shareholding
30th Jul 202112:18 pmRNSTotal Voting Rights
19th Jul 202110:21 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202110:23 amRNSTotal Voting Rights
17th Jun 202111:29 amRNSDirector/PDMR Shareholding
16th Jun 20212:13 pmRNSAdditional Listing
2nd Jun 202111:10 amRNSDirector/PDMR Shareholding
1st Jun 20219:35 amRNSBlock listing Interim Review
28th May 20211:09 pmRNSTotal Voting Rights
18th May 20214:50 pmRNSDirector Declaration
18th May 202110:32 amRNSDirector/PDMR Shareholding
17th May 202110:56 amRNSDirector/PDMR Shareholding
13th May 202110:08 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.